10 Best Healthcare Penny Stocks to Buy According to Analysts

2. Autolus Therapeutics plc (NASDAQ:AUTL)

Stock Price as of June 27: $2.31

Analyst Upside Potential as of June 27: 332.90%

Number of Hedge Fund Holders as of Q1 2025: 17

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 12, the company presented long-term follow-up data from its FELIX study at the 2025 European Hematology Association (EHA) Congress. The presentation highlighted the potential of obecabtagene autoleucel (obe-cel; brand name Aucatzyl) for long-term remission in adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL).

FELIX is a phase 1b/2, open-label, multicenter, single-arm study evaluating obe-cel in adults with r/r CD19-positive B-ALL. The study investigated obe-cel (formerly AUTO1), an autologous CD19 CAR T-cell therapy designed for rapid CAR T cell expansion and a favorable safety profile. According to the presented data, the estimated 3-year overall survival rate was 55.4%. The data also demonstrated sustained remission rates, with 40% of patients remaining in molecular remission at 36 months.

Commenting on the development, Dr. Christian Itin, Autolus CEO, said: “Obe-cel’s durability of response without any subsequent therapy in two out of every five responders is a key factor leading the transformation of therapy for adult r/r B-ALL patients. At a median follow-up of 33 months, we are encouraged to see a continuation of the long-term plateau we observed at the last data cut.”

Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company. It develops programmed T cell therapies to treat cancer and autoimmune diseases. Its lead candidate is obe-cel, a CD19-targeting treatment for adult acute lymphoblastic leukemia (ALL). Other pipeline programs include AUTO1/22 (pediatric ALL), AUTO4 (T-cell lymphoma), AUTO6NG (neuroblastoma), and AUTO8 (multiple myeloma).